Document resource
Introduction Dual antiplatelet therapy with clopidogrel is recommended for secondary prevention of atherothrombotic events after acute coronary syndrome or percutaneous coronary intervention. However, its long-term use as monotherapy remains less established (Class IIb, may be considered).Clopidogrel requires activation via the CYP2C19 pathway, and genetic variations affect metabolism. About one-third of patients carry loss-of-function polymorphisms, linked to reduced drug efficacy and increased thrombotic risk. Routine clopidogrel genetic screening in ischaemic heart disease is not currently recommended.Clinical trial success relies on patient participation, yet many studies fail to meet recruitment targets. Participation rates can vary between gender, ethnicity, and socioeconomic status, with underrepresentation of minority groups impacting the generalisability of results.This study aimed to assess patient perspectives on research participation comparing aspirin and clopidogrel.Methods A survey was distributed to patients admitted to Golden Jubilee National Hospital, Scotland, between May and October 2024. Eligible participants were those undergoing invasive coronary angiography while prescribed aspirin and clopidogrel. Responses were analysed by ethnicity, gender, and socioeconomic status. The Scottish Index of Multiple Deprivation score was calculated from post-code, which ranks areas into quintiles (Q1: most deprived, Q5: least deprived). Chi-square and Fisher’s exact tests compared categorical variables in SPSS Version 30.0.Results Patient characteristics are summarised in table 1. Among 165 participants (mean age 67.9 years), 65% were willing to participate in antiplatelet research, and 52% supported clopidogrel genotyping in a clinical trial. There were no significant differences in research participation willingness based on gender or socioeconomic status. However, patients from more deprived areas appeared to be less interested to engage in follow up (90% in Q5 versus 78% in Q1,). Most (47%) preferred receiving trial information via a text-only leaflet. Minority ethnic groups were underrepresented, limiting subgroup analysis.Abstract 2-027 Figure 1Abstract 2-027 Figure 2Abstract 2-027 Table 1Participant characteristics n (%)Conclusion There is high interest among patients to participate in anti-platelet research with a majority in support of clopidogrel genotyping within a trial. Acknowledging patient preferences for communication as well as exploring barriers to research participation may improve recruitment and retention to clinical trials. Adequate representation of minority groups within clinical research should be a priority.